Berasain C, Arecherder MG, Avila MG. Identity crisis. J Hepatol. 2023;78(2):401–1
Google Scholar
Grønkjær LL, Lauridsen MM. Quality of life and unmet needs in patients with chronic liver disease: a mixed-method systematic review. JHEP Rep. 2021;3(6):100370.
Google Scholar
Zhang CY, Yuan WG, He P, Lei JH, Wang CX. Liver fibrosis and hepatic stellate cells: etiology, pathological hallmarks and therapeutic targets. World J Gastroenterol. 2016;22(48):10512–22.
Google Scholar
Luo N, Li J, Wei Y, Lu J, Dong R. Hepatic stellate cell: a double-edged sword in the liver. Physiol Res. 2021;70(6):821–9.
Google Scholar
Caligiuri A, Gentilini A, Pastore M, Gitto S, Marra F. Cellular and molecular mechanisms underlying liver fibrosis regression. Cells. 2021;10(10):2759. https://doi.org/10.3390/cells10102759
Google Scholar
Dawood RM, El-Meguid MA, Salum GM, El Awady MK. Key players of hepatic fibrosis. J Interferon Cytokine Res. 2020;40(10):472–89.
Google Scholar
Wang Y, Wang M, Liu C, Hao M, Wang W, Li Y, et al. Global burden of liver cirrhosis 1990–2019 and 20 years forecast: results from the global burden of disease study 2019. Ann Med. 2024;56(1):2328521.
Google Scholar
Zheng S, Xue C, Li S, Zao X, Li X, Liu Q, Cao X, Wang W, Qi W, Du H, et al. Liver cirrhosis: current status and treatment options using Western or traditional Chinese medicine. Front Pharmacol. 2024;15:1381476.
Google Scholar
Ploved JM, Kelley RK, Village AG, Engines E, Roayie S, and al. Carcinoma hepose. Nat Rev Dis Disaster. 2021;7(1):6.
Google Scholar
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49.
Google Scholar
Yan Q, Sun YS, An R, Liu F, Fang Q, Wang Z, et al. Application and progress of the detection technologies in hepatocellular carcinoma. Genes Dis. 2023;10(5):1857–69.
Google Scholar
Wang C, Cao Y, Yang C, Bernards R, Qin W. Exploring liver cancer biology through functional genetic screens. Nat Rev Gastroenterol Hepatol. 2021;18(10):690–704.
Google Scholar
Anwanwan D, Singh SK, Singh S, Saikam V, Singh R. Challenges in liver cancer and possible treatment approaches. Biochimica et Biophysica Acta (BBA). 2020;1873(1):188314.
Google Scholar
Osonoi S, Takebe T. Organoid-guided precision hepatology for metabolic liver disease. J Hepatol. 2024;80(5):805–21.
Google Scholar
Zheng Z, Chen D, Lv J, Du J, Liu K. Causal effects of plasma metabolites on autoimmune hepatitis (AIH): a bidirectional two-sample Mendelian randomization study. Sci Rep. 2024;14(1):22944.
Google Scholar
Wei Z, Liu Y, Xiong Q, Mei X, Li J, Wu Z. Causality of metabolites and metabolic pathways on cholestatic liver diseases: a Mendelian randomization study. Front Med. 2024;11:1395526.
Google Scholar
Tang X, Xue J, Zhang J, Zhou J. Causal effect of immunocytes, plasma metabolites, and hepatocellular carcinoma: a bidirectional two-sample Mendelian randomization study and mediation analysis in East Asian populations. Genes. 2024 ;15(9):1183. https://doi.org/10.3390/genes15091183
Google Scholar
Gu Y, Jin Q, Hu J, Wang X, Yu W, Wang Z, Wang C, Liu Y, Chen Y, Yuan W. Causality of genetically determined metabolites and metabolic pathways on osteoarthritis: a two-sample Mendelian randomization study. J Transl Med. 2023;21(1):357.
Google Scholar
Chen Y, Lu T, Pettersson-Kymmer U, Stewart ID, Butler-Laporte G, Nakanishi T, Cerani A, Liang KYH, Yoshiji S, Willett JDS, et al. Genomic atlas of the plasma metabolome prioritizes metabolites implicated in human diseases. Nat Genet. 2023;55(1):44–53.
Google Scholar
Khanal S, Liu Y, Bamidele AO, Wixom AQ, Washington AM, Jalan-Sakrikar N, Cooper SA, Vuckovic I, Zhang S, Zhong J, Johnson KL, Charlesworth MC, Kim I, Yeon Y, Yoon S, Noh YK, Meroueh C, Timbilla AA, Yaqoob U, Gao J, Kim Y, Lucien F, Huebert RC, Hay N, Simons M, Shah VH, Kostallari E. Glycolysis in hepatic stellate cells coordinates fibrogenic extracellular vesicle release spatially to amplify liver fibrosis. Sci Adv. 2024;10(26):eadn5228. https://www.science.org/doi/10.1126/sciadv.adn5228
Tammam MA, Pereira F, Aly O, Sebak M, Diab YM, Mahdy A, El-Demerdash A. Investigating the hepatoprotective potentiality of marine-derived steroids as promising inhibitors of liver fibrosis. RSC Adv. 2023;13(39):27477–90.
Google Scholar
Xiao W, Lu MH, Rong PF, Zhang HY, Gong J, Peng YQ, Gong HY, Liu ZG. 11β–hydroxysteroid dehydrogenase–1 is associated with the activation of hepatic stellate cells in the development of hepatic fibrosis. Mol Med Rep. 2020;22(4):3191–200.
Google Scholar
Zhang YL, Li ZJ, Gou HZ, Song XJ, Zhang L. The gut microbiota-bile acid axis: a potential therapeutic target for liver fibrosis. Front Cell Infect Microbiol. 2022;12:945368.
Google Scholar
Zhang D, Zheng J, Qiu G, Niu T, Gong Y, Cui S. CCl(4) inhibits the expressions of hepatic taurine biosynthetic enzymes and taurine synthesis in the progression of mouse liver fibrosis. Hum Exp Toxicol. 2022;41:9603271221135033.
Google Scholar
Wu T, Wang M, Ning F, Zhou S, Hu X, Xin H, et al. Emerging role for branched-chain amino acids metabolism in fibrosis. Pharmacol Res. 2023;187:106604.
Google Scholar
Lee HL, Lee J, Cha JH, Cho S, Sung PS, Hur W, Yoon SK, Bae SH. Anti-fibrotic effects of branched-chain amino acids on hepatic stellate cells. Korean J Intern Med. 2022;37(1):53–62.
Google Scholar
Verbanck M, Chen CY, Neale B, Do R. Detection of widespread horizontal pleiotropy in causal relationships inferred from Mendelian randomization between complex traits and diseases. Nat Genet. 2018;50(5):693–8.
Google Scholar
Abdualkader AM, Karwi QG, Lopaschuk GD, Al Batran R. The role of branched-chain amino acids and their downstream metabolites in mediating insulin resistance. J Pharm Pharm Sci. 2024;27:13040.
Google Scholar
Newgard CB. Metabolomics and metabolic diseases: where do we stand? Cell Metab. 2017;25(1):43–56.
Google Scholar
Gunes A, Schmitt C, Bilodeau L, Huet C, Belblidia A, Baldwin C, et al. IL-6 trans-signaling is increased in diabetes, impacted by glucolipotoxicity, and associated with liver stiffness and fibrosis in fatty liver disease. Diabetes. 2023;72(12):1820–34.
Google Scholar
Kuzan A. Toxicity of advanced glycation end products (review). Biomed Rep. 2021;14(5):46.
Google Scholar
Takino JI, Sato T, Nagamine K, Sakasai-Sakai A, Takeuchi M, Hori T. Suppression of hepatic stellate cell death by toxic advanced glycation end-products. Biol Pharm Bull. 2021;44(1):112–7.
Google Scholar
Lyu C, Kong W, Liu Z, Wang S, Zhao P, Liang K, et al. Advanced glycation end-products as mediators of the aberrant crosslinking of extracellular matrix in scarred liver tissue. Nat Biomed Eng. 2023;7(11):1437–54.
Google Scholar
Bo T, Gao L, Yao Z, Shao S, Wang X, Proud CG, et al. Hepatic selective insulin resistance at the intersection of insulin signaling and metabolic dysfunction-associated steatotic liver disease. Cell Metab. 2024;36(5):947–68.
Google Scholar
Yao Z, Gong Y, Chen W, Shao S, Song Y, Guo H, et al. Upregulation of WDR6 drives hepatic de novo lipogenesis in insulin resistance in mice. Nat Metab. 2023;5(10):1706–25.
Google Scholar
Sharma V, Smolin J, Nayak J, Ayala JE, Scott DA, Peterson SN, et al. Mannose alters gut microbiome, prevents diet-induced obesity, and improves host metabolism. Cell Rep. 2018;24(12):3087–98.
Google Scholar
Lu M, Wu Y, Xia M, Zhang Y. The role of metabolic reprogramming in liver cancer and its clinical perspectives. Front Oncol. 2024;14:1454161.
Google Scholar
Liu L-x. The regulation effect and mechanism of amino acid metabolic reprograming by long non-coding RNA XIST on HCC metastasis. J Am Coll Surg. 2020;231(4, Supplement 2):e167.
Google Scholar
Su Y, Luo Y, Zhang P, Lin H, Pu W, Zhang H, Wang H, Hao Y, Xiao Y, Zhang X, et al. Glucose-induced CRL4(COP1)-p53 axis amplifies glycometabolism to drive tumorigenesis. Mol Cell. 2023;83(13):2316–e23312317.
Google Scholar
Fan W, Adebowale K, Váncza L, Li Y, Rabbi MF, Kunimoto K, et al. Matrix viscoelasticity promotes liver cancer progression in the pre-cirrhotic liver. Nature. 2024;626(7999):635–42.
Google Scholar
Gonzalez PS, O’Prey J, Cardaci S, Barthet VJA, Sakamaki JI, Beaumatin F, et al. Mannose impairs tumour growth and enhances chemotherapy. Nature. 2018;563(7733):719–23.
Google Scholar
Qiu Y, Su Y, Xie E, Cheng H, Du J, Xu Y, Pan X, Wang Z, Chen DG, Zhu H, et al. Mannose metabolism reshapes T cell differentiation to enhance anti-tumor immunity. Cancer Cell. 2025;43(1):103–e121108.
Google Scholar
Zhang C, Wang Y, He M, Wang C, Cao K, Zhong Y, et al. Mannose enhances immunotherapy efficacy in ovarian cancer by modulating gut microbial metabolites. Cancer Res. 2025;85(13):2468–84.
Google Scholar
Xia S, Xu Z, Cheng C, An R, Chen W, Lin D, et al. Blood metabolites, protein regulatory networks and their roles in pan-cancer: a Mendelian randomisation study. Discover Oncol. 2025;16(1):721.
Google Scholar
Fujiwara N, Nakagawa H, Enooku K, Kudo Y, Hayata Y, Nakatsuka T, et al. CPT2 downregulation adapts HCC to lipid-rich environment and promotes carcinogenesis via acylcarnitine accumulation in obesity. Gut. 2018;67(8):1493–504.
Google Scholar
Liu Q, Zhang X, Qi J, Tian X, Dovjak E, Zhang J, et al. Comprehensive profiling of lipid metabolic reprogramming expands precision medicine for HCC. Hepatology. 2025;81(4):1164–80.
Google Scholar
Faubert B, Solmonson A, DeBerardinis RJ. Metabolic reprogramming and cancer progression. Science. 2020;368(6487):eaaw5473.
Google Scholar
Modi AA, Feld JJ, Park Y, Kleiner DE, Everhart JE, Liang TJ, Hoofnagle JH. Increased caffeine consumption is associated with reduced hepatic fibrosis. Hepatology. 2010;51(1):201–9.
Google Scholar
Feng L, Chen X, Huang Y, Zhang X, Zheng S, Xie N. Immunometabolism changes in fibrosis: from mechanisms to therapeutic strategies. Front Pharmacol. 2023;14:1243675.
Google Scholar
Beyoğlu D, Popov YV, Idle JR. The metabolomic footprint of liver fibrosis. Cells. 2024;13(16):1333. https://doi.org/10.3390/cells13161333
Google Scholar
Xiao JF, Varghese RS, Zhou B, Nezami Ranjbar MR, Zhao Y, Tsai TH, et al. LC-MS based serum metabolomics for identification of hepatocellular carcinoma biomarkers in Egyptian cohort. J Proteome Res. 2012;11(12):5914–23.
Google Scholar
Liu SY, Zhang RL, Kang H, Fan ZJ, Du Z. Human liver tissue metabolic profiling research on hepatitis B virus-related hepatocellular carcinoma. World J Gastroenterol. 2013;19(22):3423–32.
Google Scholar
Liu Y, Hong Z, Tan G, Dong X, Yang G, Zhao L, et al. NMR and LC/MS-based global metabolomics to identify serum biomarkers differentiating hepatocellular carcinoma from liver cirrhosis. Int J Cancer. 2014;135(3):658–68.
Google Scholar
